SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-24-000068
Filing Date
2024-08-07
Accepted
2024-08-07 16:04:06
Documents
54
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20240630.htm   iXBRL 10-Q 1087740
2 EX-10.1 exhibit10110-qxq22024.htm EX-10.1 14545
3 EX-31.1 exhibit311q22024.htm EX-31.1 17233
4 EX-31.2 exhibit312q22024.htm EX-31.2 17114
5 EX-32.1 exhibit321q22024.htm EX-32.1 9845
  Complete submission text file 0001664710-24-000068.txt   4246204

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20240630.xsd EX-101.SCH 26076
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20240630_cal.xml EX-101.CAL 40880
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20240630_def.xml EX-101.DEF 130969
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20240630_lab.xml EX-101.LAB 416713
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20240630_pre.xml EX-101.PRE 273694
56 EXTRACTED XBRL INSTANCE DOCUMENT kros-20240630_htm.xml XML 298932
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 241183517
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)